Drug Trial Radar · NCT06561542
A Phase I Study of LX22001 for Injection in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Aug 5, 2024
Primary completion
Jan 23, 2025
Study completion Jan 23, 2025
Sponsor
- Lead sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD) parameters of an escalating, single dose/repeat doses of LX22001 for injection in healthy subjects.
Conditions
- Healthy
Interventions
LX22001 for InjecitonDrug
single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
Tegoprazan tabletDrug
50mg,oral,single dose
Esomeprazole sodium for injectionDrug
80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: 7 days from dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.